Literature DB >> 11089611

Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients.

H Valdez1, D Anthony, F Farukhi, A Patki, J Salkowitz, P Heeger, D L Peterson, A B Post, R Asaad, M M Lederman.   

Abstract

OBJECTIVE: To characterize immune phenotype and function in hepatitis C virus (HCV) infection in the presence and absence of HIV-1 infection.
DESIGN: Cross-sectional comparison among controls (group A), patients with HCV infection (group B), HCV-HIV-1 coinfected patients (group C), coinfected patients receiving treatment for HIV-1 (group D), and untreated HIV-1 infected patients (group E).
METHODS: Flow cytometric analysis for lymphocyte phenotypes, lymphocyte proliferation and cytokine production by ELISPOT.
RESULTS: HCV infected patients tended to have an increased percentage of activated (CD38, HLA-DR) CD8 cells (group A, 2+/-1.4%; group B, 6+/-3.9%; P=0.08). Proliferative responses to non-HCV antigens were comparable in group A and group B subjects. A greater proportion of group B patients had stimulation indices (SI) > 3 to the HCV protein NS3 compared to group C and D patients (67%, 0%, and 11% respectively; P < 0.003), but only two patients in group B had SI > or = 5. The SI to NS3 was significantly higher in group B patients [median, 4; interquartile range (IQR), 3-9) than in group C (median, 2; IQR, 1-3; P < 0.04) or group D (median, 1; IQR, 1-4; P < 0.009) patients. Plasma HCV RNA levels correlated directly with alanine aminotransferase levels (p, 0.52; P < 0.05) and inversely with the number of CD4 lymphocytes (rho, -0.55; P < 0.009) and proliferation to NS3 (p, -0.55; P < 0.009).
CONCLUSIONS: Lymphocytes of HCV infected patients show weak proliferative responses to HCV antigens while responses to other antigens are preserved. Infection with HIV-1 potentiates this deficiency. Poor CD4 T cell responses to HCV are associated with and may determine the failure to control HCV propagation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11089611     DOI: 10.1097/00002030-200010200-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  25 in total

1.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

2.  Functional impairment of CD4 T cells despite normalization of T cell number in HIV.

Authors:  Kenneth S Knox; Richard B Day; Lisa M Kohli; Chadi A Hage; Homer L Twigg
Journal:  Cell Immunol       Date:  2006-10-30       Impact factor: 4.868

Review 3.  Role of immune activation in HIV pathogenesis.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

4.  Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection.

Authors:  Camilla S Graham; Annalee Wells; Tun Liu; Kenneth E Sherman; Marion Peters; Raymond T Chung; Atul K Bhan; Janet Andersen; Margaret James Koziel
Journal:  AIDS       Date:  2006-02-14       Impact factor: 4.177

5.  Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.

Authors:  M K Jain; B Adams-Huet; D Terekhova; L E Kushner; R Bedimo; X Li; M Holodniy
Journal:  J Viral Hepat       Date:  2014-02-09       Impact factor: 3.728

6.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

7.  Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses.

Authors:  Nadia Alatrakchi; Camilla S Graham; Hans J J van der Vliet; Kenneth E Sherman; Mark A Exley; Margaret James Koziel
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

8.  Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire.

Authors:  P Ondoa; S Koblavi-Dème; M-Y Borget; M L Nolan; J N Nkengasong; L Kestens
Journal:  Clin Exp Immunol       Date:  2005-04       Impact factor: 4.330

Review 9.  HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?

Authors:  J T Blackard; K E Sherman
Journal:  J Viral Hepat       Date:  2008-01-17       Impact factor: 3.728

Review 10.  Underlying pathophysiology of HCV infection in HIV-positive drug users.

Authors:  Anuradha Balasubramanian; Jerome E Groopman; Ramesh K Ganju
Journal:  J Addict Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.